Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Partnerships 22
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
Licensing Agreements 25
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Equity Offering 31
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd – Key Competitors 34
Aslan Pharmaceuticals Pte Ltd – Key Employees 35
Aslan Pharmaceuticals Pte Ltd – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Corporate Communications 37
Jan 23, 2017: Aslan Pharmaceuticals Receives Approval To List On Taipei Exchange 37
May 30, 2016: ASLAN Pharmaceuticals appoints three new Non-Executive Directors 38
Feb 29, 2016: Aslan Pharmaceuticals Appoints Andrew Howden As Independent Director 39
Product News 40
04/21/2016: New Data On Aslan’s Varlitinib To Be Published At 2016 Annual Meeting Of American Society Of Cancer Oncology 40
02/23/2016: Aslan Pharmaceuticals To Present New Data On Varlitinib At Annual American Association For Cancer Research Meeting 41
01/24/2017: Aslan Pharmaceuticals To Present At The Cholangiocarcinoma Foundation Annual Conference 2017 42
Product Approvals 43
Feb 19, 2017: ASLAN Pharmaceuticals receives Orphan Drug Designation in Korea for varlitinib (ASLAN001) in biliary tract cancer 43
Jun 24, 2016: ASLAN receives Orphan Drug Designation for varlitinib in gastric cancer 44
Clinical Trials 45
Jun 07, 2017: Aslan Pharmaceuticals Announces New Positive Data Identifying ASLAN003 As A Novel Therapeutic Agent In Acute Myeloid Leukaemia 45
Feb 13, 2017: Aslan Pharmaceuticals Announces First Patient Enrolled In Phase 1 Study Of Varlitinib In Japan 46
Feb 09, 2017: ASLAN Pharmaceuticals reports positive top-line results for phase 2 clinical trial of varlitinib in metastatic breast cancer 47
Appendix 48
Methodology 48
About GlobalData 48
Contact Us 48
Disclaimer 48
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Key Facts 2
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Aslan Pharmaceuticals Pte Ltd, Deals By Therapy Area, 2011 to YTD 2017 9
Aslan Pharmaceuticals Pte Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Aslan Pharma Raises USD23 Million in Venture Financing 13
Aslan Pharma Raises Additional USD9 Million in Venture Financing 15
Aslan Pharma Raises USD34 Million in Series C Financing 17
Aslan Pharma Raises US$22 Million In Series B Financing 19
Aslan Pharma Raises US$12 Million In Series A Financing 21
Aslan Pharma Enters into Agreeement with Cancer Science Institute Of Singapore and National University Cancer Institute 22
Aslan Pharma Enters into MoU with National Cancer Centre Singapore 23
ASLAN Pharma Enters into Agreement with ACT Genomics 24
ASLAN Pharma Enters into Licensing Agreement with Nanyang Technological University 25
ASLAN Pharma Enters into Licensing Agreement with Agency for Science, Technology and Research 26
Hyundai Pharma Enters into Licensing Agreement with Aslan Pharma 27
Aslan Pharma Enters Into Licensing Agreement With CSL For CSL-334 28
Aslan Pharma Expands Licensing Agreement with Almirall for LAS186323 29
Array BioPharma Enters Into Licensing Agreement With ASLAN Pharma For ARRY-543 30
Aslan Pharma Plans to Raise USD84 Million in Public Offering of Shares 31
Aslan Pharma Plans to Raise Funds through Private Placement of Shares 32
Aslan Pharma Raises USD33.2 Million in IPO 33
Aslan Pharmaceuticals Pte Ltd, Key Competitors 34
Aslan Pharmaceuticals Pte Ltd, Key Employees 35
Aslan Pharmaceuticals Pte Ltd, Other Locations 36
Aslan Pharmaceuticals Pte Ltd, Subsidiaries 36